The success of Sildenafil initially drove a boom for pharma, but recent changes present a complicated scenario for those considering a stake. Lower-cost competitors are eroding profits, and persistent litigation add https://majasptq836435.blog-eye.com/41529818/the-blue-pill-and-pharma-a-volatile-play